A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma

Status:
Terminated

Trial end date:
2018-11-16

Target enrollment:

Participant gender:

This is a study to determine the safety of CDX-014 and effectiveness (how well the drug works).

Phase 1

Celldex Therapeutics